Products
Companies
News
About
About
Add your product
Contact
Newsletter
×
Subscribe to our monthly newsletter
Subscribe
Products
Veolity
Veolity
MeVis Medical Solutions AG
Veolity LungRead is a reading solution dedicated to lung screening programs as well as incidental pulmonary nodule management. It combines lung CAD of solid, non-solid, part-solid, and calcified pulmonary nodules, automatic nodule type classification, volumetric nodule quantification, interactive temporal comparison and nodule tracking, and creates a guideline-compliant report. Veolity supports reporting according to Lung-RADS, BTS Guidelines, BC Lung Screening Protocol incl. Nodule Malignancy Risk Estimation (according to the Brock model).
Veolity’s AI automatically marks regions that are suggestive of pulmonary nodules to identify regions that demand further analysis and may have been previously overlooked by the human eye.
Information source:
Vendor
Last updated:
Nov. 26, 2023
General Information
Technical Specifications
Regulatory
Market
Evidence
General Information
General
Product name
Veolity
Company
MeVis Medical Solutions AG
Subspeciality
Chest
Modality
CT
Disease targeted
Lung Cancer
Key-features
Nodule detection, segmentation and quantification, temporal registration and nodule comparison, report generation according to guidelines
Suggested use
Before: flagging acute findings
During: perception aid (prompting all abnormalities/results/heatmaps), interactive decision support (shows abnormalities/results only on demand), report suggestion
Technical Specifications
Data characteristics
Population
Chest CTs on an asymptomatic population
Input
3D chest CT
Input format
DICOM
Output
CAD report, CAD overlay, radiology report
Output format
DICOM SR, DICOM SC, DICOM GSPS, XML, PDF, TXT
Technology
Integration
Integration in standard reading environment (PACS), Integration RIS (Radiological Information System), Integration CIS (Clinical Information System), Stand-alone third party application
Deployment
Locally on dedicated hardware, Locally virtualized (virtual machine, docker)
Trigger for analysis
Automatically, right after the image acquisition
Processing time
Regulatory
Certification
CE
Certified, Class IIa
, MDR
FDA
510(k) cleared , Class II
Intended Use Statements
Intended use (according to CE)
Veolity is intended to • display a composite view of 2D cross-sections, and 3D volumes of chest CT images, • allow comparison between new and previous acquisitions as well as abnormal thoracic regions of interest, such as pulmonary nodules, • provide Computer-Aided Detection (“CAD”) findings, which assist radiologists in the detection of solid pulmonary nodules between 4-30 mm in size in CT images with or without intravenous contrast. CAD is intended to be used as an adjunct, alerting the radiologist – after his or her initial reading of the scan – to regions of interest that may have been initially overlooked. The system can be used with any combination of these features. Enabling/disabling is handled via licensing or configuration options.
Market
Market presence
On market since
03-2015
Distribution channels
Blackford, Myrian
Countries present (clinical, non-research use)
25+ (including Europe, USA, Canada, Australia, Republik of Korea, Hong Kong, New Zealand)
Paying clinical customers (institutes)
500+
Research/test users (institutes)
Veolity is used in several clinical trials world-wide
Pricing
Pricing model
Based on
Evidence
Evidence
Peer reviewed papers on performance
Assisted versus Manual Interpretation of Low-Dose CT Scans for Lung Cancer Screening: Impact on Lung-RADS Agreement
(read)
Non-peer reviewed papers on performance
Other relevant papers